Expanded Access Programm Fosmanogepix (APX001-901 EAP)

EPICOVIDEHA - Epidemiology of COVID-19 infection in patients with hematological malignancies: A European Haematology Association Survey

Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus specie (OASIS)

An interventional efficacy and safety Phase 3 double-blind 2-arm study to investigate IV followed by oral fosmanogepix compared with IV caspofungin followed by oral fluconazole in adult participants with candidemia and/or invasive candidiasis.

Fecal microbiota transfer for the secondary prevention of recurrent urinary tract infections in premenopausal women: a phase II trial

FungiScope - A Global Rare Fungal Infection Registry

Physiological effect of Glp-1 receptor activation on reward and effort learning in obesity

A phase 2, multicentre, open-label, single arm study to evaluate the effectiveness and safety of rezafungin (as acetate) in the treatment of chronic pulmonary aspergillosis (CPA) in patients with limited treatment options

A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides difficile Infection in Individuals 18 Years of Age and Above

A Randomized controlled open-label phase II trial assessing the efficacy and safety of two-dosing regimens of frozen encapsulated fecal microbiota transfer products with or without an individualized donor selection approach in decolonizing carriers of multi-drug resistant Enterobacteriaceae

VACCELERATE - Volunteer Registry Database for studies against SARS-CoV-2 and other infectious agents

A randomized, double-blind, placebo-controlled phase 3 study of VE303 for prevention of recurrent CLOSTRIDIOIDES DIFFICILE infection: THE RESTORATIVE303 STUDY